Erratum to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease (CNS Drugs, (2018), 32, 4, (387-398), 10.1007/s40263-018-0498-4)

Lawrence W. Elmer, Jorge L. Juncos, Carlos Singer, Daniel D. Truong, Susan R. Criswell, Sotirios Parashos, Larissa Felt, Reed Johnson, Rajiv Patni

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 March 2018. An error was subsequently identified in the article, and the following correction should be noted.

Original languageEnglish (US)
Pages (from-to)399-400
Number of pages2
JournalCNS Drugs
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erratum to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease (CNS Drugs, (2018), 32, 4, (387-398), 10.1007/s40263-018-0498-4)'. Together they form a unique fingerprint.

Cite this